Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen ...

Early initiation of moderate-intensity aerobic exercise reduced pain compared with standard care among postmenopausal women who received aromatase inhibitors.

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

In the case of breast cancer, women with a higher BMI do have higher rates of recurrence compared to women in the "normal" ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Osenvelt is indicated to prevent skeletal-related events in patients ...

It is administered orally and is prescribed in combination with an aromatase inhibitor as an initial endocrine-based therapy. Additionally, the drug is being developed for the treatment of ...